$1.31
-0.05 (-3.69%)
Open$1.22
Previous Close$1.36
Day High$1.32
Day Low$1.17
52W High$2.95
52W Low$0.80
Volume—
Avg Volume1.33M
Market Cap179.05M
P/E Ratio—
EPS$-0.35
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+359.8% upside
Current
$1.31
$1.31
Target
$6.00
$6.00
$4.29
$6.00 avg
$7.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 54.9K | 9.23M | 9.01M |
| Net Income | -93,052,366 | -678,125 | -522,642 |
| Profit Margin | -155,587.4% | -7.4% | -5.8% |
| EBITDA | -97,566,407 | -963,511 | -904,753 |
| Free Cash Flow | — | -508,030 | -465,093 |
| Rev Growth | — | +6.0% | +24.9% |
| Debt/Equity | 0.02 | 0.23 | 0.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |